Company Description
NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific.
The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system.
It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.
The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data.
In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications.
Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits.
The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics.
NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bank
| Country | United States |
| Founded | 2003 |
| IPO Date | Jun 26, 2013 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 550 |
| CEO | R. Bradley Gray |
Contact Details
Address: 530 Fairview Avenue North Seattle, Washington 98109 United States | |
| Phone | 206-378-6266 |
| Website | nanostring.com |
Stock Details
| Ticker Symbol | NSTGQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401708 |
| ISIN Number | US63009R1095 |
| Employer ID | 20-0094687 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| R. Bradley Gray | Chief Executive Officer, President and Director |
| K. Thomas Bailey M.B.A. | Chief Financial Officer |
| Dr. Joseph M. Beechem Ph.D. | Chief Scientific Officer and Senior Vice President of Research and Development |
| Mark A. Winham | Senior Vice President of Operations |
| Douglas S. Farrell | Vice President of Investor Relations and Corporate Communications |
| Kathryn Surace-Smith | Senior Vice President of Human Resources and Legal Affairs and Corporate Secretary |
| Elizabeth Schneider Ph.D. | Senior Global Marketing Manager |
| Dr. Philippa Webster Ph.D. | Senior Principal Scientist |
| Todd Garland | Chief Commercial Officer |
| Praveer Sharma | Field Application Scientist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | 8-K | Current Report |
| Apr 19, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 25-NSE | Filing |
| Mar 22, 2024 | 8-K | Current Report |
| Mar 15, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 12, 2024 | 8-K | Current Report |
| Mar 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |